Variability of Insulin Action: Does It Matter?

Insulin

Volumn 3, Issue 1, 2008, Pages 37-45

  Heinemann, Lutz ^a  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

Author keywords

basal insulin; inhalation; insulin; insulin therapy; pharmacodynamics; pharmacokinetics; prandial insulin; variability

Indexed keywords

CORTISONE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; MONOCOMPONENT INSULIN; NEUTRAL INSULIN; PIG INSULIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG RESPONSE; EVIDENCE BASED MEDICINE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; LIPODYSTROPHY; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE BLOOD FLOW;

EID: 40249113289     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(08)80010-3     Document Type: Article

References (17)

1. Muggeo M., Zoppini G., Bonora E., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: The Verona Diabetes Study. Diabetes Care 23 (2000) 45-50
2. Ziel F., Davidson M., Harris M., and Rosenberg C. The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption. Diabet Med 5 (1988) 662-666
3. Heinemann L., Weyer C., Rauhaus M., et al. Variability of the metabolic effect of soluble insulin and the rapid acting insulin analogue insulin aspart. Diabetes Care 21 (1998) 1910-1914
4. Galloway J., Spradlin C., Howey D., and Dupre J. Intrasubject differences in pharmacokinetic and pharmacodynamic responses: The immutable problem of present-day treatment. In: Serrano-Rios M., and Lefebvre P. (Eds). Diabetes 1985 (1986), Excerpta Medica, Amsterdam, The Netherlands 877-886
5. Heinemann L., Sinha K., Weyer C., et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 16 (1999) 332-338
6. Scholtz H., Pretorius S., Wessels D., and Becker R. Pharmacokinetic and glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48 (2005) 1988-1995
7. Heinemann L., Klappoth W., Rave K., et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23 (2000) 1343-1347
8. Brunner G., Balent B., Ellmerer M., et al. Dose-response relation of liquid aerosol inhaled insulin in type 1 diabetic patients. Diabetologia 44 (2001) 305-308
9. Pfützner A., Heise T., Steiner S., et al. Inhaled Technosphere/Insulin shows a low variability in metabolic action in type 2 diabetic patients [abstract]. Diabetes 49 (2000) A121
10. Perera A., Kapitza C., Nosek L., et al. Absorption and metabolic effect of inhaled insulin: Intra-patient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 25 (2002) 2276-2281
11. Heinemann L. Insulin pharmacology. In: Pickup J., and Williams G. (Eds). International Textbook of Diabetes 2 (2003), Blackwell Science Ltd, Massachusetts, USA; Oxford, UK; Victoria, Australia; Berlin, Germany 42.1-42.15
12. Moore E., Mitchell M., and Chalmers T. Variability in absorption of insulin-I 131 in normal and diabetic subjects after subcutaneous and intramuscular injection. J Clin Invest 38 (1959) 1222-1227
13. Galloway J., Spradlin C., Nelson R., et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 4 (1981) 366-376
14. Berger M., Cüppers H., Hegner H., et al. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 5 (1982) 77-91
15. Heise T., Nosek L., Ronn B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
16. Jehle P., Micheler C., Jehle D., et al. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 354 (1999) 1604-1607
17. Patton J., Bukar J., and Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 35 (1999) 235-247